Article
NNMT drives innate sensitivity to NAMPT inhibition in YAP-dependent stem-like/ mesenchymal prostate cancer
2025-05-02
Abstract excerpt
<h4>ABSTRACT</h4> Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD+ salvage pathway and a promising therapeutic target in cancer. Resistance to NAMPT inhibitors, such as FK866, remains a key limitation to their clinical translation. While acquired resistance in cancer cell lines has been linked to target mutations, increased drug efflux and metabolic reprogramming, innate resi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7d7c6aa3-e597-5142-a6a7-beb123fa47d0
- DOI
- 10.1101/2025.04.29.651153
